Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 71-80 of 201 for melanoma

Edit search filters
  1. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

    Scottsdale/Phoenix, AZ

  2. Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

    Jacksonville, FL

  3. A Study to Assess the Safety and Tolerability of ADI-PEG 20 Combined with Pemetrexed and Cisplatinin in Subjects with Tumors Requiring Arginine

    Rochester, MN

  4. A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

  5. A Study to Evaluate the DermaSensor Tool on Skin Lesions Suggestive of Skin Cancer

    Rochester, MN

  6. Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

    Rochester, MN

  7. A Study to Evaluate RP1 Monotherapy and Combined with Nivolumab

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  9. Therapeutic Drug Monitoring of Pembrolizumab and Nivolumab to Determine Dosages for Cancer Treatment

    Rochester, MN

  10. In-home Versus In-Clinic Subcutaneous Nivolumab Administration through Connected and Remote Cancer CARE Beyond Walls

    Jacksonville, FL

.

Mayo Clinic Footer